drugset / Trial / NCT06713590

A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants

NCT06713590

Phase 1 Completed 72 enrolled Incyte Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will be conducted to evaluate a Single-Dose Subcutaneous (SC) Axatilimab Compared With Intravenous Axatilimab in Healthy Participants.

Timeline

Start
2025-01-14
Primary completion
2025-06-06
Completion
2025-06-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Axatilimab Monoclonal antibody Intravenous

Indications

No indication recorded.